Efanesoctocog alfa

From WikiMD's Wellness Encyclopedia

Efanesoctocog alfa is a recombinant DNA derived, coagulation factor VIII (FVIII) product, indicated for use in the control and prevention of bleeding episodes in patients with hemophilia A. It is a long-acting, human FVIII molecule with a single glycopeptide that extends its half-life in circulation.

Mechanism of Action[edit | edit source]

Efanesoctocog alfa works by replacing the missing coagulation FVIII that hemophilia A patients need for effective hemostasis. The FVIII is activated by thrombin and functions as a cofactor for factor IXa which, in the presence of calcium and phospholipids, converts factor X to the activated form (Xa). The factor Xa then converts prothrombin into thrombin, which leads to fibrin clot formation.

Pharmacokinetics[edit | edit source]

Efanesoctocog alfa is administered intravenously. The pharmacokinetics of efanesoctocog alfa are similar to those of other FVIII products. The half-life of efanesoctocog alfa is extended due to the single glycopeptide, allowing for less frequent dosing.

Adverse Effects[edit | edit source]

The most common adverse effects of efanesoctocog alfa include headache, rash, and fever. Serious adverse effects may include development of FVIII inhibitors, which can lead to a loss of clinical response. In such cases, alternative therapies may be required.

Contraindications[edit | edit source]

Efanesoctocog alfa is contraindicated in patients who have had life-threatening hypersensitivity reactions to the product or its components.

Drug Interactions[edit | edit source]

No specific drug interactions have been identified with efanesoctocog alfa. However, it should be used with caution in patients receiving concomitant anticoagulants.

References[edit | edit source]

Contributors: Prab R. Tumpati, MD